EN
Instrument Fundamentals
| Date | Close | Change | Change (%) | Open | High | Low |
|---|
News
Pfizer On Pace for Largest Percent Increase Since May — Data Talk | Morningstar
HEALTHCARE: Pfizer (PFE: A2/A): 2025 Guidance
Pfizer Signals Growth in FY 2025 Guidance, Projects Revenue Up to $64 Billion
Pfizer (NYSE:PFE) Issues FY24 Earnings Guidance
Pfizer (NYSE:PFE) Updates FY25 Earnings Guidance
Stocks making the biggest moves premarket: PFE, TSLA, SEDG, RCAT and more
Pfizer Sees 2025 Revenue in Line With Wall Street Views — Update | Morningstar
In relief for investors, Pfizer 2025 profit forecast in line with estimates | Company News - Business Standard
Nvidia, Evgo and Affirm fall premarket; Pfizer and SolarEdge rise By Investing.com
Pfizer (NYSE:PFE) Releases FY 2025 Earnings Guidance
Pfizer Sees 2025 Revenue in Line With Wall Street Views, Despite Hit from Benefit Changes | Morningstar
Pfizer’s In-Line Guidance Offers Relief to Weary Investors
Is Pfizer Inc. (PFE) the Best Weight Loss Stock to Buy Now According to Hedge Funds?
Pfizer forecasts 2025 profit in line with expectations as it seeks turnaround
Pfizer Expects 2025 Adj. EPS Operational Growth Of 10% To 18%; Reaffirms 2024 Guidance
US health-care stocks dip on Trump's commitment to PBM reform By Investing.com
Pfizer projects 2025 earnings to align with expectations By Investing.com
Lava Therapeutics' SWOT analysis: stock faces challenges after key asset discontinuation By Investing.com
Symbol: PFE Security name: Pfizer CDR (CAD Hedged) Status:
Pfizer (NYSE:PFE) Trading Up 0.5% - Here's Why
Arbutus Biopharma's SWOT analysis: hepatitis B focus drives stock potential By Investing.com
Pfizer (PFE) Gets a Hold from Wells Fargo | Markets Insider
Pfizer's SWOT analysis: stock outlook amid pipeline progress and market challenges By Investing.com
Sangamo Therapeutics' SWOT analysis: gene therapy firm's stock faces hurdles By Investing.com
Beaird Harris Wealth Management LLC Reduces Holdings in Pfizer Inc. (NYSE:PFE)
Pfizer (PFE) Is Too Cheap To Ignore
Pfizer Inc. (NYSE:PFE) Position Trimmed by B. Riley Wealth Advisors Inc.
Franklin Resources Inc. Has $477.76 Million Position in Pfizer Inc. (NYSE:PFE)
Tidal Investments LLC Grows Holdings in Pfizer Inc. (NYSE:PFE)
World Investment Advisors LLC Purchases 48,281 Shares of Pfizer Inc. (NYSE:PFE)
Inspire Trust Co. N.A. Purchases 14,891 Shares of Pfizer Inc. (NYSE:PFE)
Truist sees upside in Sangamo stock with milestone payments and Fabry disease advancements By Investing.com
Pfizer (NYSE:PFE) Stock Price Up 0.3% After Dividend Announcement
Copley Financial Group Inc. Buys New Stake in Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) Shares Sold by Denver PWM LLC
Cim Investment Management Inc. Reduces Holdings in Pfizer Inc. (NYSE:PFE)
Synovus Financial Corp Acquires 78,675 Shares of Pfizer Inc. (NYSE:PFE)
Sanctuary Advisors LLC Has $22.35 Million Holdings in Pfizer Inc. (NYSE:PFE)
Q1 Earnings Estimate for Pfizer Issued By Leerink Partnrs
51,783 Shares in Pfizer Inc. (NYSE:PFE) Bought by Virtu Financial LLC
Y Intercept Hong Kong Ltd Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)
Pfizer Inc. (NYSE:PFE) Increases Dividend to $0.43 Per Share
Pfizer Inc (PFE) Announces Increase in Quarterly Dividend for Q1 2025
Moderna Stays Upbeat As Anti-Vaxxers Prepare To Rule In D.C. 12/12/2024
Pfizer Boost Quarter Dividend by 2.4% to 43 Cents | Morningstar
Pfizer Declares First-Quarter 2025 Dividend | Morningstar
Pfizer (NYSE:PFE) Trading Up 0.8% - Time to Buy?
Pfizer Inc. (NYSE:PFE) Shares Sold by Sunbelt Securities Inc.
TD Private Client Wealth LLC Acquires 3,307 Shares of Pfizer Inc. (NYSE:PFE)
Riot Platforms Stock Jumps After Starboard Takes Stake in Bitcoin Miner - Markets Insider
Pfizer Inc. (NYSE:PFE) Shares Purchased by Westside Investment Management Inc.
Destination Wealth Management Buys 38,907 Shares of Pfizer Inc. (NYSE:PFE)
PATINA trial demonstrates benefit of palbociclib in HR+ HER2+ metastatic breast cancer
Arvest Bank Trust Division Buys Shares of 485,143 Pfizer Inc. (NYSE:PFE)
Pfizer Declares $0.43 Quarterly Dividend; 6.8% Yield By Investing.com
Pfizer's Phase 3 PATINA Trial Shows Promising Results for IBRANCE in Breast Cancer Treatment
Pfizer reports extended survival in breast cancer trial By Investing.com
Morse Asset Management Inc Buys New Position in Pfizer Inc. (NYSE:PFE)
Leerink Partnrs Has Negative Outlook for Pfizer Q4 Earnings
Soltis Investment Advisors LLC Sells 159,325 Shares of Pfizer Inc. (NYSE:PFE)
Pfizer raises dividend to $0.43 per share for Q1 2025 By Investing.com
Pfizer (NYSE:PFE) Earns Neutral Rating from Bank of America
Pfizer raises quarterly dividend to 43c per share | Markets Insider
Amazon Pharmacy, Pfizer Discuss Hot Temperatures -- And Hot Topics 12/12/2024
CADL Stock Soars as Phase III Prostate Cancer Study Meets Primary Goal - December 12, 2024 - Zacks.com
Pfizer (NYSE:PFE) Stock Price Down 0.4% Following Analyst Downgrade
Amazon, Pfizer execs seek common ground with RFK Jr on climate risks to health
Guggenheim Lowers Pfizer (NYSE:PFE) Price Target to $33.00
Brown Financial Advisors Has $1.27 Million Stake in Pfizer Inc. (NYSE:PFE)
McIlrath & Eck LLC Sells 813 Shares of Pfizer Inc. (NYSE:PFE)
Pfizer (NYSE:PFE) Stock Price Up 2.4% – What’s Next?
Guggenheim cuts Pfizer shares target, keeps Buy rating ahead of guidance By Investing.com
Financial Avengers Inc. Increases Stock Holdings in Pfizer Inc. (NYSE:PFE)
Arete Wealth Advisors LLC Takes Position in Pfizer Inc. (NYSE:PFE)
Toronto Dominion Bank Reduces Stock Holdings in Pfizer Inc. (NYSE:PFE)
Neo Ivy Capital Management Raises Stake in Pfizer Inc. (NYSE:PFE)
Pfizer stock outlook dims as 2025 EPS guidance reflects normalization of COVID business By Investing.com
Is Pfizer Inc. (PFE) the Best American Dividend Stock to Buy Right Now?
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study - December 11, 2024 - Zacks.com
NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines - December 11, 2024 - Zacks.com
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug - December 11, 2024 - Zacks.com
Pfizer Thailand Reaffirms Commitment to Expanding Access to Innovative Medicines
FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates - December 11, 2024 - Zacks.com
Pfizer (NYSE:PFE) Shares Down 1.1% - What's Next?
Pfizer Inc (PFE) Announces Upcoming Webcast for 2025 Financial Guidance
Frisch Financial Group Inc. Has $994,000 Stock Holdings in Pfizer Inc. (NYSE:PFE)
Arvinas, Pfizer Report Positive Data From Phase 1b Study Of Vepdegestrant Combination Therapy | Markets Insider
First Dallas Securities Inc. Trims Holdings in Pfizer Inc. (NYSE:PFE)
The Sri Lanka Institute of Nanotechnology (SLINTEC) witnessed a remarkable transformation - with four patents having been commercialised, with an additional four innovations in the advanced stage of commercialisation. Under the leadership of Thilan Wijesinghe, Investment Banker and PPP Specialist who took over as Chairman of SLINTEC in September 2022, and CEO Dr Thushara Vajera Perera (formerly a Senior Scientist at Pfizer Inc., USA, and Director - Innovation Health Science and Technology at MAS, Sri Lanka), SLINTEC has propelled forward towards global recognition, financial self-sufficiency, and groundbreaking contributions to Sri Lanka’s industrial innovation landscape. Prior to the leadership transition at SLINTEC in 2023, over its 16-year history since its establishment in 2008, the institution had commercialised approximately seven patents and innovations, averaging fewer than two commercialisations per year. In addition, up to 2022, SLINTEC had faced significant challenges, including a notable loss of 80+ scientists over four years and financial constraints affecting operational sustainability. Today, the organisation’s remarkable growth highlights its strengthened ability of a newly energised team of scientists led by Dr Perera to convert scientific innovations into practical, market-ready solutions. Speaking with Chairman, SLINTEC - Thilan Wijesinghe noted, “SLINTEC’s revenue in 2024 reached a record high and is poised to be eclipsed in 2025. At present, SLINTEC is the only research-based institution that does not rely on Government funding for recurring expenses. An institution with 50% shareholding by the National Science Foundation and 50% by private sector companies such as MAS, LOLC, Brandix and Hayleys, SLINTEC now serves as a model for public-private collaboration in advancing scientific innovation in Sri Lanka.” The organisation’s commitment to sustainability is demonstrated through R&D focused on natural dyes – a strategy adopted to position SLINTEC as a global leader in this area and to assist growth and innovation in Sri Lanka’s apparel industry. In this regard, two patents have already been commercialised including coconut husk and palm oil waste-based natural dyes, as well as a patent based on packaging material made using agricultural waste such as corn husk. Commenting on the success of the organisation, CEO, SLINTEC - Dr. Thushara Perera stated: “It is our vision to make SLINTEC Sri Lanka’s most valuable science-based asset through structured commercialisation of R&D. We hope to drive SLINTEC to become a hub for cutting-edge research and sustainability-driven innovation while forging impactful partnerships with industry, local and international universities and R& D establishments, covering a multititle of sectors such as minerals, agriculture and export manufacturing.” - DailyNews
Continuum Advisory LLC Grows Stock Position in Pfizer Inc. (NYSE:PFE)
Bank of America Reaffirms Neutral Rating for Pfizer (NYSE:PFE)
Lilly CEO says tax and regulation reform, drug affordability are focuses under Trump By Reuters
Pfizer Inc. (NYSE:PFE) Shares Acquired by Geode Capital Management LLC
